|
2024
|
Invention
|
Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones.
Compounds of Formula (I) are provide... |
|
|
Invention
|
Wee1 inhibitor for cancer.
Disclosed herein is a WEE1 compound, or a pharmaceutically acceptable... |
|
|
Invention
|
Use of combination therapy for treating cancer.
Disclosed herein are combinations of compounds f... |
|
|
Invention
|
Combinations.
Disclosed herein are combinations of compounds for treating a disease or condition... |
|
|
Invention
|
Combination therapies comprising wee1 inhibitors and dna damage response (ddr) inhibitors.
Discl... |
|
|
Invention
|
Combinations of wee1 inhibitors and anti-cd47 antibodies.
Disclosed herein are combinations of c... |
|
2023
|
Invention
|
Wee1 inhibitors and methods for treating cancer.
Disclosed herein is a method of determining sub... |
|
|
Invention
|
Benzamide compounds.
Compounds of Formula (I) are provided herein. Such compounds, as well as ph... |
|
|
Invention
|
Wee1 inhibitors and methods for treating cancer. Compounds of general Formula (I) are provided he... |
|
|
Invention
|
Combinations. This application discloses a combination therapy using a combination of a WEE1 inhi... |
|
|
Invention
|
Wee1 compound for treating uterine serous carcinoma. Disclosed herein are methods of identifying ... |
|
|
Invention
|
Benzamide compounds. Compounds of Formula (I) are provided herein. Such compounds, as well as pha... |
|
2022
|
Invention
|
Use of combination therapy for treating cancer. Disclosed herein are combination therapies compri... |
|
|
Invention
|
Wee1 inhibitor for cancer. Disclosed herein is a WEE1 compound, or a pharmaceutically acceptable ... |
|
|
Invention
|
Triple therapy combinations of bcl-2 inhibitors, wee-1 inhibitors and other chemotherapeutic agen... |
|
|
Invention
|
Treating osteoporosis. Disclosed herein is the use of Compound (A), or a pharmaceutically accepta... |
|
|
Invention
|
Combination therapies comprising wee1 inhibitors and dna damage response (ddr) inhibitors. Disclo... |
|
|
Invention
|
Combinations of wee 1 inhibitors and anti-cd47 antibodies.. Disclosed herein are combinations of ... |
|
|
Invention
|
Immunoconjugates and methods. Immunoconjugates of the Formula (I) include a linking group for lin... |
|
|
Invention
|
Tricyclic compounds. Disclosed herein are tricyclic compounds, together with pharmaceutical compo... |
|
|
Invention
|
Wee1 inhibitors and methods for treating cancer. Disclosed herein is a method of determining subj... |
|
|
Invention
|
Wee1 compound for treating uterine serous carcinoma.
Disclosed herein is a method for treating a... |
|
|
Invention
|
Wee1 compound for treating uterine serous carcinoma. Disclosed herein is a method for treating a ... |
|
|
Invention
|
Estrogen receptor modulators. Compounds of Formula (I) are estrogen receptor alpha modulators, wh... |
|
2021
|
Invention
|
Combinations of bcl-2 inhibitors with chemotherapeutic agents.
The present invention relates to ... |
|
|
Invention
|
Salts and forms of a wee1 inhibitor.
The salt, such as adipate salt Form A, and freebase forms o... |
|
|
Invention
|
Methods of making wee1 inhibitor compounds.
A process is provided for making a WEE1 inhibitor of... |
|
|
Invention
|
Mono- and combination therapies.
Disclosed herein are compounds and combinations of compounds fo... |
|
|
Invention
|
Combinations.
Disclosed herein are combination therapies of Bcl-2 inhibitors (Compound (A), alon... |
|
|
Invention
|
Bcl-2 protein inhibitors.
Various Bcl-2 protein inhibitors are described, along with methods of ... |
|
|
Invention
|
Preparation of an selective estrogen receptor degrader.
Described herein is a method for obtaini... |
|
|
Invention
|
Difluoromethyl iodo compounds and methods.
The present application is related to an improved pro... |
|
2020
|
Invention
|
Chiral synthesis of a tertiary alcohol.
Disclosed herein are methods for preparing tertiary alco... |
|
|
Invention
|
Salts and forms of an estrogen receptor modulator.
Salts of Compound A and forms described herei... |
|
|
Invention
|
Process for making [1.1.1]propellane. Processes of making [1.1.1]propellane utilize reaction cond... |
|
|
Invention
|
Nanoparticle formulation of bcl-2 inhibitor.
Various albumin nanoparticle Bcl-2 inhibitor formul... |
